New Hope for Multiple Sclerosis Treatment with Biologically Validated Myelin Repair
The protein DDX39B is a master regulator of immune tolerance and helps to control the development of immune cells that are key for this process, according to a new study. Activating DDX39B with small molecules might be a viable strategy for treating autoimmune diseases like multiple sclerosis (MS), where the immune tolerance process is disrupted. The study also found that DDX39B changes the expression of genes considered to be MS risk factors, suggesting that DDX39B may itself affect the risk of MS or other autoimmune diseases.